Member Info for Saxondale

Bexmarilimab is rapidly advancing through development and its exciting clinical activity across multiple cancer types continues to give us confidence in this asset's potential as a next generation immunotherapy with broad opportunities. With the data we have seen to-date, we are pleased to expand our bexmarilimab development programme

correction to that last waffle of mine - meant 2021 Q2 .
And also would add that I wrote it yesterday in a rush so not really a properly thought argument as such - that would take many pages and even more waffle .
At the end of day , its a simple decision to make , whether you have faith in the companys future or not . Its a gamble of pros and cons vs what SP you are averaging and how much you have , and are you prepared to lose it all or see it half instantly should terrible news emerge . That's the same with every share I guess .
I like the story here , I like and trust the CEO . That's a trait that runs through all my other main holdings EUA , GGP SNG and NCYT . And similarly with all of them , if things work out , the gains will be huge .

Pot , I do see where you are coming from , regarding the future of Traumakine .
We have shown our hand on Traumakine - it failed once , not twice , and after some explaining and negotiating with FDA , it still has a shot , but agreed , it's been compromised by the discovery about steroids . If it was proven to be a worthless therapy though , Faron should have binned it and gone 100% onto Clevegen . But they still saw it as a viable treatment ( like you say if administered correctly ) . THE FDA don't usually allow further phase 3 trials for a failed drug unless there is a good reason . The further research and patent regarding the polymorphism aspect , and also the patent for monitoring the treatment will give any further trial much more clarity . Then you have the trial being run absolutely in conjunction with our old nemesis , steroids . Partners were being lined up for Calibre , and you would expect the same for Hibiscus . The WHO debacle is scientifically a non event , despite it wrecking the SP for us , so any partner they had lined up should still be on talking terms . The downside of the steroids should be outweighed greatly by the potential windfall any partner will reap if Faron run a successful P3 trial . The fact that drugs are being bought in bulk by Govts and given FDA approval even when they don't seem to work , really does mean the bar is set pretty low for what is seen as a success . I don't recall seeing a budget for the trial , but its going to be funded by a third party I guess , as Markku has stated many times . The soft loans were for Traumakine manufacture and freeze dried techincal stuff . Why use the money for that if you didn't have any means of paying for the trial to get you there ? That's the way I see it . He must have something lined up , otherwise its all back to front .

Clevegen - again - its been very quiet - budget is there too see them through Q1 , and some left for further collaborations with cancer IO etc , but yes , its cards on the table time soon . I think we will see one or two cohort top line results , and I see some being better than others ( due to the quality of patients they have been able to enroll) . The possible partnering scenarios should be alot healthier here , and again , Markku seems very buoyant about this . We can only put our faith in him that things are going to work out . He is keen to avoid unnecessary dilution . Yes , we've had 2 or 3 placings , but its enabled us to keep 100% ownership , and hence the windfall on a success will be the maximum .
I think he's played it well to get us this far with so little dilution , considering Clevegen is a real cash burner .

Would I put my house on the SP being £25 by 2020 Q2 . No
But I've got a fair wedge on it being a good side better than £2.75 .
Worse case scenario - Clevegen results poor - SP drops and they have to do another £1.90 placing . But I just can't see it . Markku is pretty confident that Shareholder value is coming .

I've tried emailing them a couple of times to ask a few questions , such as when they plan to announce any further findings . Never get a reply .
33 odd therapies being trialed , but with 4000 odd Covid patients enrolled and it being an adaptive trial , you'd have though we would be up there , particularly when we are up against treatments such as Vitamin D . I know which one I'd want to try if I was gasping for breath .

BBC article from May 2020
https://www.bbc.co.uk/news/health-52805828

from that article - UK regulators say there is enough evidence to approve its use in selected Covid-19 hospital patients.
Minister for Innovation Lord Bethell said: "This shows fantastic progress"
I wonder what UK regulators are thinking today ?

Our good friends at the WHO have just published this bonfire p*sser for Remdesivir .

https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients

Looks like they will be running what they call a ' living guideline ' , offering guidance on therapies as new evidence comes to light .
https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline
Hope they have plenty of Tipex , when they get around to revisingthe Interferon report .

No harm in slicing some for other ventures Cagney . Glad you've kept a good chunk here though , as you'd kick yourself if a cracking Clevegen RNS landed next week . I suppose for many in your position , a 3-4 bagger should be classed as a successful investment , but like you obviously have , many have got somewhat emotionally attached to this share and the story of the plucky underdog . Regarding missing the boat , I don't think a few months will mean missing the boat with Traumakine . Look at SNG , they will get results probably Jan-Feb - and will make a killing if it works out . Likewise with Faron . Plus , as we are not a vaccine or a specific therapy for Covid , if phase 3 is successful , the opportunities will be plentiful .
This share has been a series of long waits , I'll grant you that . I didn't think I'd be hanging on for years either . Mind you I could have cashed in a £5 and walked away with plenty of profit , but I wouldn't have been satisfied .
At least this time , the jam tomorrow situation is coming to a point where its going to be either jam or no jam . I'm expecting plenty of jam so just holding for the well deserved payday .

Thanks Axe and those for giving us the details .
Sat looking at the SP this morning , and I just couldn't fathom why it was still stuck there . Vaccine news has come and gone , and even if another 10 get similar results , it won't fix the problem for at least the next 5 years , if ever . And then there's the next virus.
So I bought some more again .
Two big reasons to now hold until the endgame - The data set - outstanding . and the CEO , also in my opinion top drawer .
With AIM companies , the CEO is the backbone of the company .
Phase 3 will be a walk in the park , just need to sit on hands now for a bit .

I must admit , a nice steady £2.70 has been almost a relief this last week , after many of us holding pharma stocks have had our pants pulled down and given a good spanking this week , and it's been a wake up call for me about getting complacent about what an SP should be , and how much I should be investing in some of these smaller firms whose SPs are tossed about like loose ships in a storm when Gobal news/ rumours break . The only way to sleep at night is to either be incredibly rich already ( not yet ) , treat your shares like a pension and check them once a year ( again , not possible as I have too much free time and no willpower ) , or just run half of your holding as a loose float , chopping in and out so that a price fall becomes an opportunity . I've started doing that on a few now , although not without a few disasters and panic sales that I later regretted . Some days I feel like contestant on Bob Monkhouses golden shot in my share trading decisions . So I think rather than rainbow chasing profit day by day , I need to take a step back sometimes and just let the SP come to me . Painful in the short term , but like they say , nothing goes up in a straight line ( although unfortunately many things do come down that way ) . Q4 update please ;-)

5.6 million euros funding for Immune research in Turku University headed up by no other than Professor and Academician Sirpa Jalkanen , wife of Markku , and an outstanding scientist in her own right .

Not sure how or if Faron may play a part in this , but great to see them get such substantial funding - showing how serious they are .

https://www.utu.fi/en/news/news/flagship-initiative-in-immune-system-research-and-drug-development-receives

FP-1305 induces robust T-cell activation and downregulation of immune checkpoint
expression.

Lots of complicated biology in the paper - but from what I can glean , its all positive obviously and backs up the science behind Clevegen , or bexmarilimab as we should start thinking of it ( what will be written on the invoice lol )

Our results reveal a non-redundant role played by the receptor Clever-1 in suppressing adaptive immune cell activation in humans. We provide evidence that targeting macrophage scavenging activity can promote an immune switch potentially leading to intratumoral proinflammatory responses in metastatic cancer patients.

Faron website had a few updated pages today . Nothing of major interest , but I see Haematokine now has its own page .

Hematopoietic Stem Cell Transplantation (HSCT) is standard of care in many hematological malignancies. Transplant failure is a lethal complication and is a result of poor expansion of transplanted cells, which can occur in over 25% of patients. Haematokine is the expansion of hematopoietic stem cells by regulating AOC3 activity for the use in regenerative medicine and hematological malignancies. This program, currently in pre-clinical development, has the potential to benefit all indications where an expansion of haemopoietic stem cells is needed.

Luckily I filled my boots 2 days ago . All this press attention should put some wind in the sails . I still can't believe the SP went down so much anyway - either investors are massively short sighted , or just sheep these days ? Anyone who understands what SNG are doing with Interferon ( along with Faron and their I/V route ) , and NCYT in their domain should and probably have been topping up big time this week .

I suppose those of us who thought that the science was enough , were probably a bit naive . The big Pharma want to stay big , and Covid will be a massive cash cow for some . Every country's Health system is 'owned' to some degree by these companies . Its a bit like the Arms Industry , its an elite club . At the end of the day though , if Traumakine or Clevegen are a success , the big Pharma will make the most money out of it in the end , they'll just have to buy or license the IP off Faron . Thats about the only protection these little companies have , the patents .
Once the big boys have had their time in the trough selling Remdesivir , Hydroxychloroquine , and Atheletes foot powder to all the Govts in the world , we'll be allowed in to have a go .

That patent that Faron filed in 2019 for spotting the polymorphism that certain people have that has a big influence on whether Interferon therapy will be effective could well be even more important in Covid choice of treatment .
Those who have the polymorphism are more receptive to I/V Interferon treatment .
Depending on your racial make up - some have more than others .
Biggest racial group that have it - those of African origin ( 40-45% ) . Caucasian is about 30-35% .

Recent studies seem to bear out the already reported data that more black people seem to go down with Covid . The actual reasons why this is arent totally clear ( social / job / living vs a genetic reason ) - but at least Faron have identified those parts of the population that will respond better to I/V IFN Beta1a . And if this pattern of infection plays out worldwide - that fact combined with the fact that Traumakine will statistically be more effective on patients from African origin should be a big plus for the practical use of the therapy .

https://patents.justia.com/patent/20200199677

https://www.bbc.co.uk/news/health-54907473

What a message to send . Fantastic . Plus he's gonna make some serious money , and who can blame him .

Two more virtual conferences in the next 3 weeks for Markku to present at , plus a virtual conference Faron are attending ( Jefferies 2020 - the largest healthcare-dedicated conference in Europe )
Jefferies conference - 17-19th Nov

The 2 events where Markku is presenting

Piper Sandler - Investment banking group specialising in Partnerships . 1-3rd Dec
Evercore - another massive Investment banking group also 1-3rd Dec

Both huge global businesses , US based .

Hopefully he may have some interested ears listening to the multitude of Clevegen partnering opportunities .

LSE seems to have lost my part2 - it may pop back up - nothing much more to add other than they seem to be learning more and more about Clevegen as the data rolls in . Simple blood test can help them check progress , and also Markku talked of how once the tumour has been reduced , remission should be permanent in that particular cancer , as the body's immune system knows how to combat it .
At the moment it seems to be a balance between getting as much data in to satisfy potential partners and running out of cash .and needing more funding . However , as he says - show me a pharmaceutical discovery company that isn't in the same position - that's how they work . He does seem very optimistic that although a major deal may not happen immediately , the unveiling of new data soon WILL add value , as investors will see where this could lead . In fact he had a couple of slides showing the market potential - and that as a combination drug - there is literally no limit .

Anyway - all in all - good to see him being positive . Hopefully it will have gained us a few more investors - to catch up with all those ones in Finland !

CLEVEGEN - interesting to hear Markku talk again of the safety of Clevegen - very good - opens it up to be used as a combi therapy as there are no real side effects etc . The same process is used in the placenta of the womb .
Also interesting that he thinks that once Clevegen has battled the tumour , the body will always be able to fight that same cancer as it will recognise it - so remission should be permanent ( in that cancer ) .

5.) REMAP - He does sound happy with their design - but no inside track on when an update may come .

6.) USA - With Hibiscus starting , they felt they needed a USA based person on their Advisory team - hence the enrollment of Prof Tyler Curiel from san Antonio - further making progress in their foot in the door in the USA .

7.) Rentchler arbitration - still ongoing - sees some conclusion in the middle of next year at the latest - may be a handy injection of funds if it goes farons way .

8.) Lots of other little tidbits he dropped in , particularly about the freeze dried format of Traumakine - and how distribution and use will be very straightforward . All in all - he seemed still very positive and upbeat about progress . Still not adding much info about the new A0c3 inhibitors , so the secret weapon status still active there lol .

Anyway , on the back of that injection ( sorry) of optimism , I bought a few more shares :-)